caa a22 4500 463186001 CHVBK 20180406164853.0 cr unu---uuuuu 170326e20070201xx s 000 0 eng 10.1007/s00726-006-0319-9 doi (NATIONALLICENCE)springer-10.1007/s00726-006-0319-9 The role of group I metabotropic glutamate receptors in schizophrenia [Elektronische Daten] [M. Pietraszek, J. Nagel, A. Gravius, D. Schäfer, W. Danysz] Summary.: It has been proposed that glutamatergic transmission, in particular NMDA receptor function, might be altered in schizophrenia. This hypothesis is mainly based on the observation that uncompetitive NMDA receptor antagonists, e.g. phencyclidine, evoke psychotic symptoms in healthy subjects, whereas agonists interacting at the glycine site of the NMDA receptor complex, e.g. glycine or D-serine, administered jointly with typical neuroleptics, can alleviate schizophrenic symptoms. The function of NMDA receptors may be modulated by group I mGluRs (mGluR1 and mGluR5), which have also been shown to be altered in schizophrenia. In rodents, mGluR5 antagonists, but not mGluR1 ones, potentiate the locomotor activity and the deficit of prepulse inhibition (PPI) induced by uncompetitive NMDA receptor antagonists. These antagonists (of either type) administered alone are not active in the above tests. Hence, antagonists of mGluR1 and mGluR5 may evoke different effects on the NMDA receptor antagonists-induced behavior and, possibly, on schizophrenic symptoms. Springer-Verlag, 2006 Keywords: NMDA receptors - mGluR1 - mGluR5 - Prepulse inhibition - Locomotor activity - Schizophrenia nationallicence Pietraszek M. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut Nagel J. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut Gravius A. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut Schäfer D. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut Danysz W. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut Amino Acids Springer-Verlag 32/2(2007-02-01), 173-178 0939-4451 32:2<173 2007 32 726 https://doi.org/10.1007/s00726-006-0319-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00726-006-0319-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pietraszek M. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut NATIONALLICENCE 700 1- Nagel J. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut NATIONALLICENCE 700 1- Gravius A. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut NATIONALLICENCE 700 1- Schäfer D. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut NATIONALLICENCE 700 1- Danysz W. Preclinical R&D, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany aut NATIONALLICENCE 773 0- Amino Acids Springer-Verlag 32/2(2007-02-01), 173-178 0939-4451 32:2<173 2007 32 726 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer